Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
- 30 September 2007
- Vol. 41 (3) , 308-317
- https://doi.org/10.1016/j.bone.2007.06.010
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Raloxifene enhances vertebral mechanical properties independent of bone densityBone, 2006
- In VivoAssessment of Trabecular Bone Microarchitecture by High-Resolution Peripheral Quantitative Computed TomographyJournal of Clinical Endocrinology & Metabolism, 2005
- Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention TrialOsteoporosis International, 2004
- Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention TrialJournal of Bone and Mineral Research, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugsThe American Journal of Medicine, 2002
- Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic womenBone, 2000
- Bone resorption and formation on the periosteal envelope of the ilium: A histomorphometric study in healthy womenJournal of Bone and Mineral Research, 1992
- Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.Journal of Clinical Investigation, 1988
- Active Bone Turnover of the Cortico-Endosteal Envelope in Postmenopausal Osteoporosis*Journal of Clinical Endocrinology & Metabolism, 1987